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Abstract
Type 1 diabetes is an autoimmune disease whereby components of insulin-secreting pancreatic beta cells are targeted by the 
adaptive immune system leading to the destruction of these cells and insulin deficiency. There is much interest in the devel-
opment of antigen-specific immune intervention as an approach to prevent disease development in individuals identified as 
being at risk of disease. It is now recognised that there are multiple targets of the autoimmune response in type 1 diabetes, the 
most recently identified being a member of the tetraspanin family, tetraspanin-7. The heterogeneity of autoimmune responses 
to different target antigens complicates the assessment of diabetes risk by the detection of autoantibodies, as well as creat-
ing challenges for the design of strategies to intervene in the immune response to these autoantigens. This review describes 
the discovery of tetraspanin-7 as a target of autoantibodies in type 1 diabetes and how the detection of autoantibodies to the 
protein provides a valuable marker for future loss of pancreatic beta-cell function.
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Introduction
Type 1 diabetes is an autoimmune disease that results from 
the specific loss of insulin-secreting pancreatic beta cells 
leading to severe insulin deficiency and the requirement for 
insulin replacement therapy. The disease is associated with 
an inflammation within pancreatic islets, the clusters of cells 
within the pancreas where the beta cells are located, that is 
usually dominated by  CD8 + cytotoxic T-cells, with lower 
numbers of  CD4+ helper T-cells, antibody producing B-cells 
and macrophages [1]. There is a genetic association of type 
1 diabetes with HLA loci, specifically those associated with 
the presentation of antigens to  CD4+ T-cells (HLA-DR3, 
HLA-DR4, HLA-DQ8), confirming an important role of the 
immune system in disease [2]. More than 90% of patients 
who develop type 1 diabetes have circulating autoantibod-
ies to components of the affected tissue, the hallmark of 
autoimmune disease. Furthermore, these autoantibodies may 
appear many years before disease onset, providing valuable 
predictive markers for the future development of type 1 dia-
betes [3]. The availability of tools capable of identifying 
people at risk of developing type 1 diabetes, combined with 
the knowledge that the disease is caused by autoimmune 
destruction of beta cells, has led to a search for reagents 
capable of blocking autoimmune responses to the pancre-
atic beta cell to prevent disease developing in those identi-
fied as being at risk of disease. Indeed, immune interven-
tion aimed at inactivating or depleting T-cells or B-cells 
has already shown promise in maintaining some residual 
beta-cell function during clinical trials involving patients 
with recent-onset type 1 diabetes, and more recently in those 
identified as being at high risk [4–7]. More effective tools for 
intervening in the immune response would be targeted very 
specifically at those immune responses directly involved in 
beta cell destruction, which requires identification of the 
targets of B-cells and T-cells that are activated in the disease. 
This review focuses on a member of the tetraspanin family, 
tetraspanin-7 (Tspan7) that has recently been discovered as 
a potentially important target of autoimmune responses in 
type 1 diabetes [8].
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Identification of islet cell autoantigens 
in type 1 diabetes
In 1982, Baekkeskov et al. [9] described studies in which 
proteins within isolated human islets were metabolically 
labelled with radiolabelled amino acid and extracts sub-
jected to immunoprecipitation with antibodies in sera 
from patients with type 1 diabetes or from non-diabetic 
control individuals. In those experiments, distinct proteins 
of molecular weights 64 kDa and 38 kDa were immu-
noprecipitated by antibodies specifically found in sera 
from patients with type 1 diabetes. Since 1982, extensive 
research has been undertaken on the identification of tar-
gets of autoantibodies in type 1 diabetes, the development 
of assays for reliable detection of these autoantibodies 
and the design of strategies to use such assays in disease 
prediction. The 64 kDa protein originally described by 
Baekkeskov et al. was subsequently shown to represent 
two major targets of autoimmunity in type 1 diabetes: the 
65 kDa isoform of glutamic acid decarboxylase (GAD65) 
and a tyrosine phosphatase-like protein, IA-2 [10, 11]. In 
addition, insulin and a zinc transporter, ZnT8, have also 
been demonstrated to be major targets of autoimmunity in 
the disease [12, 13]. Antibodies to all of these molecular 
targets are rarely detected in non-diabetic individuals. In 
people who develop diabetes, these autoantibodies appear 
months to years before the clinical onset of type 1 diabetes 
[14, 15], and often first appear within the first 5 years of 
life [16], making islet autoantibodies important markers 
for the identification of people at risk of developing type 
1 diabetes, even in early childhood.
Using autoantibodies to predict type 1 
diabetes
A large number of studies have been performed to deter-
mine how the measurement of islet autoantibodies may 
be used to identify people at risk of developing type 1 
diabetes. Having accurate markers for disease risk will be 
important for the introduction of disease prevention ther-
apy. Most studies have been undertaken in families with 
type 1 diabetes, measuring islet autoantibodies in non-
diabetic offspring or siblings of the proband with follow 
up for any later appearance of the disease. Some studies 
have followed family members from birth, providing valu-
able information on the time of appearance of individual 
islet autoantibodies and relationship to disease [14–17]. 
Such prospective studies on autoantibody appearance have 
demonstrated a progressive appearance of autoantibodies 
to insulin, GAD65, IA-2 and ZnT8, with insulin often the 
first antibody specificity to appear, often within the first 
five years of life [15–17]. There may be individuals where 
autoantibodies to GAD65 appear first at a later age [18]. 
Diversification of the immune response to multiple islet 
antigens appears to be critical for progression to type 1 
diabetes; individuals who develop antibody responses to 
a single autoantigen without further diversification rarely 
develop type 1 diabetes, at least within the follow-up 
period of studies reported to date [19, 20]. Furthermore, 
no single antibody marker is able to provide optimum 
sensitivity and specificity for disease prediction. Instead, 
risk of progression to type 1 diabetes is best evaluated 
by assessing the number of individual antibody markers 
that are positive in a serum sample [19–21]. Currently, a 
combination of autoantibodies to insulin, GAD65, IA-2 
and ZnT8 are often used to assess diabetes risk. The addi-
tion of new autoantibody markers may further improve our 
ability to predict type 1 diabetes, particularly when using a 
strategy where positivity for multiple antibodies provides 
the measure of risk.
Identification of Glima 38 as tetraspanin‑7
Whilst the nature of the “64 k antigen” originally described 
by Baekkeskov et al. [9] was defined some years ago as 
two distinct proteins, the 65 kDa isoform of glutamate 
decarboxylase and IA-2 [10, 11], the identity of the 38 kDa 
component recognised by autoantibodies in type 1 diabetes 
has proved more elusive. Aanstoot et al. [22] performed a 
more extensive analysis of the nature of 38 kDa proteins 
immunoprecipitated from radiolabelled islets and cell lines 
by antibodies in type 1 diabetes together with an estimate 
of the proportion of patients positive for these antibodies. 
In that study, the authors showed that the 38 kDa protein 
partitioned into the detergent phase on phase separation 
in Triton-X114, a property characteristic of amphiphilic 
membrane proteins [23]. Furthermore, the protein resolved 
on SDS polyacrylamide gels as diffuse smears rather than 
sharp bands (Fig. 1), that was typical of heavily glyco-
sylated membrane proteins. Indeed, deglycosylation of the 
protein with N-glycanase reduced the molecular weight 
of the protein to 22 kDa, indicating that the antigen has 
a high carbohydrate content. Substantial N-linked glyco-
sylation of the antigen was further illustrated by a simi-
lar reduction in size when cells were incubated with the 
N-glycosylation inhibitor, tunicamycin, and by the ability 
of the protein to bind to the lectin, wheat germ agglutinin 
[24]. Since autoantibodies in patients’ sera were able to 
immunoprecipitate the non-glycosylated protein, the car-
bohydrate element appears irrelevant to antibody binding 
[22, 24]. Furthermore, the autoantibody target was found 
to be expressed in islet and neuronal cell lines, but not 
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in a range of other transformed cell lines derived from 
other tissues, suggesting that, similar to other diabetes-
associated autoantigens GAD65 and IA-2, the protein is 
specifically expressed in neuroendocrine tissues. Aanstoot 
et al. [22] dubbed the autoantigen Glima 38 (for Glycos-
lated Islet Membrane Antigen of 38 kDa).
The discovery of these specific characteristics of the 
novel autoantigen was expected to facilitate identification of 
the Glima 38 autoantigen [24], but a further 15 years were to 
elapse before the molecular identity of Glima 38 was finally 
defined. McLaughlin et al. took a proteomic approach to 
sequence fragments of proteins immunoprecipitated specifi-
cally by antibodies in sera from Glima 38-antibody-postive 
patients [8]. The authors demonstrated that high Glima 38 
immunoreactivity could be detected in normal islets, brain, 
pituitary and lung and, for the purpose of Glima 38 purifica-
tion and identification, amphiphilic membrane glycoproteins 
were isolated from extracts of brain and lung by Triton-X114 
phase separation and wheat germ agglutinin affinity chro-
matography. These extracts were then further affinity puri-
fied using bead-conjugated antibodies isolated from sera 
of patients strongly positive or negative for Glima 38 anti-
bodies. Eluates were separated by SDS polyacrylamide gel 
electrophoresis and 38 kDa bands treated with trypsin and 
analysed by liquid chromatography with tandem mass spec-
trometry (LC–MS/MS). The proteomic analysis identified 
three proteins present in both lung and brain extracts that 
were specifically eluted from the Glima 38 antibody-positive 
affinity beads but not from the negative control, and only 
one, tetraspanin-7, had the biochemical properties of Glima 
38 described above. Tetraspanin-7 (Tspan7) was confirmed 
as a target of autoantibodies in type 1 diabetes by the abil-
ity to immunoprecipitate both the natural and recombinant 
protein expressed by cell lines by autoantibodies in patients’ 
sera [8].
Tspan7 is a 4-transmembrane domain protein with expres-
sion restricted to the central nervous system, to endocrine 
organs including the pancreatic islet and the pituitary, and to 
the lung [8]. Functional aspects of Tspan7 and the potential 
importance of the protein in neuronal development, viral 
infection and cancer are reviewed in this Special Issue [25]. 
There is evidence that the protein plays a role in vesicle 
trafficking in the cells of the nervous system and Tspan7 
may regulate the surface expression of specific receptor 
molecules [25–27]; part of its function may be mediated 
by interaction with specific partner proteins [25, 27–29]. 
Mutations in Tspan7 have been associated with X-linked 
intellectual disability [25, 30–32] and impaired vesicle traf-
ficking, cell surface receptor expression or dysregulated 
synapse development in the absence of functional Tspan7 
may provide the molecular basis of the condition [25–27]. 
The role of Tspan7 in pancreatic islets is unknown, but one 
can speculate that the protein may also have a role in vesicle 
trafficking, given the secretory functions of cells in which 
the protein is expressed.
Detection of autoantibodies to tetraspanin‑7
A number of different assay formats are available for the 
detection of circulating antibodies to autoantigens associated 
with type 1 diabetes. Many of the research studies designed 
to quantify autoantibodies to GAD65, IA-2 and ZnT8 in type 
1 diabetes have used radioligand binding assays in which 
radiolabelled antigen is generated by transcription and 
translation of the protein in vitro using appropriate plasmid 
Fig. 1  Immunoprecipitation of 38  kDa protein (Glima 38) by anti-
bodies in sera from patients with type 1 diabetes. Proteins within 
the rat pancreatic beta-cell line, RIN 5AH, were radiolabelled with 
35S methionine by incubation of the cells in medium containing 35S 
methionine. Proteins were extracted from labelled cells in Triton 
X-114 and subjected to temperature-induced phase separation to iso-
late amphiphilic membrane proteins (ref). Radiolabelled membrane 
proteins were incubated with sera from patients with type 1 diabe-
tes overnight, immune complexes captured on protein A Sepharose, 
washed and separated by SDS PAGE. The figure shows the results of 
immunoprecipitation reactions with 16 patients with type 1 diabetes 
(1–16), two non-diabetic control samples (C), and two Glima 38 posi-
tive control samples. Diffuse 38 kDa bands, characteristic of heavily 
glycosylated membrane proteins such as the tetraspanin family, were 
specifically immunoprecipitated by antibodies in sera from patients 
with type 1 diabetes
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constructs in the presence of radiolabelled amino acid. The 
translates are then incubated with serum samples, antibody-
bound radiolabelled antigen captured on protein A Sepharose 
and quantified by scintillation counting [11]. Radioactivity 
immunoprecipitated then provides an indication of autoan-
tibody levels. The protocol provides a relatively simple and 
versatile means to quantify diabetes-associated antibodies 
and the assay format has shown good reproducibility and 
performance in international diabetes autoantibody stand-
ardisation workshops [33–36]. Unfortunately, soon after the 
discovery of Tspan7 as an autoantibody target it was clear 
that radioligand binding assays with antigen transcribed and 
translated in vitro were not capable of detecting diabetes-
associated Tspan7 antibodies effectively [8, 37].
The binding of autoantibodies to their target autoanti-
gens in type 1 diabetes and other autoimmune disorders is 
very often highly dependent on the conformation of the tar-
get antigen, involving interaction with amino acids which 
may be quite far apart on the linear sequence of the protein, 
but which are located close together in the natural three-
dimensional structure of the protein [38–40]. Production of 
the target antigen with appropriate three-dimensional struc-
ture is, therefore, critical for efficient autoantibody detec-
tion by immunoassay. The overall structure of tetraspanins, 
with four transmembrane domains, three short cytoplasmic 
domains and two glycosylated ectodomains (Fig. 2), presents 
a number of challenges for the development of assays for 
antibodies to the Tspan7 protein. Firstly, the hydrophobic 
nature of the protein, as a consequence of the four trans-
membrane domains, complicates its purification for use in 
immunoassays (for example ELISA or RIA) and may lead to 
high non-specific binding in various assay formats. Assays 
for antibodies to the transmembrane autoantigens IA-2 and 
ZnT8 usually have their transmembrane domains removed 
to avoid these issues [11, 13]. Secondly, if Tspan7 antibody 
epitopes involve amino acids from more than one of the three 
cytoplasmic domains, or from both ectodomains, then proper 
membrane insertion and alignment of the transmembrane 
domains may be required to form the epitope. This may not 
happen when Tspan7 is transcribed and translated in vitro 
and may explain the failure of Tspan7 antibody assays using 
protein expressed in this manner.
An alternative approach has, therefore, been taken to 
express Tspan7 in a form that can be bound by autoanti-
bodies and easily detected and quantified. The assay format 
currently used is the luminescent immunoprecipitation sys-
tem (LIPS) [8], in which the target antigen is expressed as a 
fusion protein with a luciferase tag that is incubated with test 
antibodies [41]. Antibody-bound luciferase-tagged antigen 
is captured on protein A Sepharose and quantified by lumi-
nometry after addition of a luciferase substrate. For Tspan7 
antibody assays, the antigen is expressed as a recombinant 
protein after transfection of vector into mammalian cells, 
to increase chances of the protein folding naturally dur-
ing protein synthesis. Because there is the potential for the 
interference of antibody binding to the antigen by the large 
luciferase tag, Tspan7 has been expressed as a fusion with 
nanoLuciferase, which is one of the smaller and brighter 
luciferases currently available.
Unlike radioligand binding assays with antigen transcribed 
in vitro, LIPS assays have proved capable of detecting of 
Tspan7 autoantibodies in type 1 diabetes [8]. Nevertheless, 
there have been issues with sensitivity and specificity of 
autoantibody detection by LIPS. Firstly, antibodies in a sig-
nificant number of non-diabetic control samples have been 
shown to bind to the Tspan7-luciferase fusion protein, reduc-
ing the specificity of the assay [8, 37]. For these non-diabetic 
Fig. 2  Model of structure of tetraspanin-7. The three-dimensional 
structure of Tspan7 was modelled by SWISS-MODEL [56] using the 
structure of CD81 as template. The figure shows the short and long 
ectodomains in green and orange, respectively, the four transmem-
brane domains arranged in a cone-like structure in red and the three 
short cytoplasmic domains arranged close together in blue. Epitopes 
for antibodies in type 1 diabetes are likely to lie within the cytoplas-
mic domains
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controls, natural or recombinant Tspan7 lacking a luciferase 
tag fails to block antibody binding, indicating that these anti-
bodies are not specific to the Tspan7 molecule but rather bind 
a structure created by the fusion of Tspan7 with luciferase. To 
improve specificity, some Tspan7 autoantibody assays include 
a blocking step with untagged Tspan7, with effective inhibition 
of binding being an indication of Tspan7-specific binding [37]. 
Unfortunately, the higher specificity of this approach may be 
achieved at the expense of lower sensitivity.
The second problem observed with Tspan7 LIPS is that 
some samples in which Glima 38 antibodies were detected 
by immunoprecipitation assays with radiolabelled Glima 38 
were negative in the LIPS, thereby reducing the sensitivity 
of the Tspan7 antibody assay [8]. Whilst it is possible that 
38 kDa bands detected on autoradiographs after immunopre-
cipitation by antibodies in Type 1 diabetes sera may include 
proteins other than Tspan7, a more likely explanation is that 
some Tspan7 autoantibody epitopes may not be accessible 
on the recombinant antigen, either as a consequence of steric 
hindrance by the luciferase tag or because of issues with the 
conformation of Tspan7 when expressed as a recombinant 
protein; recombinant protein hyperexpression in mammalian 
cell expression systems may result in significant protein mis-
folding. Alternatively, it is known that several tetraspanins 
bind cholesterol [42] and structural analysis of the tetraspa-
nin CD81 has revealed that the four transmembrane domains 
form a pocket in which cholesterol may bind. Incorporation 
of cholesterol into the CD81 structure dramatically alters the 
conformation of the tetraspanin [43]. If cholesterol-mediated 
conformational changes also occur for Tspan7, autoantibody 
binding may be disrupted because of alterations in the struc-
ture of the antibody epitope.
Further characterisation of antibody binding to chimeric 
or truncated constructs of Tspan7 has suggested that autoan-
tibody epitopes lie predominantly within the first and third 
cytoplasmic domains, with potential antibody-contact residues 
identified at the C-terminal end of the protein by amino acid 
substitutions incorporated by site-directed mutagenesis [44, 
45]. Autoantibody epitopes, therefore, lie within a relatively 
short (20-amino acid) region represented by at least two of 
the three cytoplasmic domains, providing further evidence of 
the importance of protein conformation in antibody binding. 
Establishing procedures to express or synthesise constructs 
that maintain the integrity of the autoantibody epitopes will 
be important for reliable detection of Tspan7 antibodies as 
markers of type 1 diabetes.
Value of autoantibodies to tetraspanin‑7 
in diabetes prediction and prevention
The detection of autoantibodies to insulin, GAD65, IA-2 
and ZnT8 has proved valuable for prediction and diag-
nosis of type 1 diabetes, has provided insights into dis-
ease pathogenesis and into the heterogeneity of immune 
responses that appear in individuals developing the dis-
ease. Identification of target autoantigens also opens up 
the possibility of specifically blocking immune responses 
to individual target antigens to prevent disease progres-
sion in those at risk, without the hazards associated with 
the administration of general immunosuppression. With 
the identification of a fifth major target in Tspan7, the 
question then arises as to the importance of Tspan7 auto-
immunity to diabetes prediction and prevention. Because 
of the difficulties of establishing reliable Tspan7 antibody 
assays, there are currently very few studies addressing 
these questions.
Aanstoot et al. [22], using immunoprecipitation assays 
with radiolabelled cell extracts and assessing the presence 
of antibodies by detecting bands on autoradiographs, anti-
bodies to Glima 38 (i.e. Tspan7) were found in only 19% 
of 86 recently diagnosed patients with type 1 diabetes 
aged 0.8–57 years. Antibodies to Glima 38 were found 
in a similar proportion (14%) of non-diabetic individu-
als who later developed type 1 diabetes and were present 
3–74 months before disease onset. Glima 38 antibodies 
were not found in non-diabetic controls. Thus, Tspan7 
autoimmunity can appear years before disease onset and 
may, therefore, be useful in disease prediction, but its 
value may be limited by the low proportion of patients 
positive for the antibodies.
Using a similar assay, with operators blinded to the 
identity of each sample, Winnock et al. [46] detected Glima 
38 antibodies in a higher proportion, 38%, of patients with 
recent-onset type 1 diabetes (aged 0–39 years) and in 35% 
of non-diabetic individuals who later developed the dis-
ease. Similar to the Aanstoot study, Glima 38 antibodies 
were detected between 3 and 77 months before disease 
onset. None of 100 non-diabetic controls were positive in 
the assay. The differences in antibody frequencies between 
the two studies are likely due to problems in evaluating a 
positive result from the diffuse bands on autoradiographs, 
as the intensity of bands varies substantially between 
patients (Fig. 1). One might expect that introduction of 
quantifiable assays using recombinant antigen would 
improve the reproducibility and sensitivity, of Tspan7 
autoantibody detection.
McLaughlin et al. [8], using a direct Tspan7 antibody 
LIPS, detected antibodies in 43% of 94 patients with 
recent-onset type 1 diabetes aged 12–63 years, and in 1 of 
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94 non-diabetic controls. The frequency of Tspan7 anti-
bodies is higher in children than adults [47]. Walther et al. 
[37], using a similar LIPS assay but including a blocking 
step with untagged Tspan7, detected Tspan7 antibodies in 
35% of 269 patients with recent-onset type 1 diabetes aged 
7–13 years and positive for other islet autoantibodies, in 
3.2% of 94 patients negative for islet autoantibodies and 
in 22% of 114 non-diabetic individuals considered at high 
risk of diabetes by having multiple antibodies to insulin, 
GAD65, IA-2 or ZnT8. Follow up of these high-risk indi-
viduals indicated that the addition of Tspan7 antibodies 
as a predictive marker resulted in a small but insignificant 
increase in the probability of diabetes progression [37].
It is now evident that diabetes is a heterogeneous disorder 
and tools that aid the categorisation of diabetes are needed 
to assist in providing the best treatments for individuals who 
develop the disease. For example, 10–15% of people initially 
diagnosed with type 2 diabetes are found to have evidence 
of beta-cell autoimmunity in the form of circulating islet 
autoantibodies and often progress to an insulin-requiring 
form of diabetes termed latent autoimmune diabetes in 
adults (LADA). Autoantibodies to GAD65 are commonly 
detected in LADA, whereas the frequency of those to insu-
lin, IA-2 and ZnT8 are lower than found in acute-onset type 
1 diabetes. LADA is generally considered to be a slow pro-
gressing form of autoimmune diabetes, perhaps associated 
with a less aggressive autoimmune response to pancreatic 
beta-cell antigens, with fewer patients having antibodies to 
multiple islet autoantigens.
Shi et al. [48] have recently examined the role of Tspan7 
autoantibodies in type 1 diabetes and LADA in patients 
recruited in China. The prevalence of type 1 diabetes in 
Asia is lower than in the West and, in Asian patients who 
develop disease, antibodies to the established islet antigens 
such as IA-2 and ZnT8 are present at a lower frequency. 
For measurement of autoantibodies in the Chinese patients, 
the authors used a Tspan7 LIPS assay with a blocking step 
using untagged Tspan7 to confirm specificity, as developed 
by Walther et al. [37]. Antibodies to Tspan7 were detected in 
26% of the Chinese type 1 diabetes patients, lower than the 
frequency of Tspan7 antibodies found in Caucasian patients 
with a similar assay [37]. Antibodies to IA-2 and ZnT8 were 
also lower in Chinese type 1 diabetes than in Caucasian 
patients, and the addition of Tspan7A antibodies did not 
significantly alter the proportion of patients identified with 
at least one islet autoantibody (from 82 to 84%). In contrast, 
measurement of Tspan7 antibodies was of value in predict-
ing a decline in beta-cell function in Chinese patients with 
LADA. The addition of Tspan7 antibody analysis signifi-
cantly increased the proportion of Chinese LADA patients 
with multiple antibodies and Tspan7 antibody positivity was 
associated with lower fasting and postprandial C-peptide 
levels, indicative of poorer pancreatic beta-cell function. 
Furthermore, the presence of Tspan7 antibodies predicted 
a faster decline in pancreatic beta-cell function in Chinese 
LADA patients, demonstrating that the novel autoantibody 
marker has value in predicting metabolic outcomes in spe-
cific diabetes patient groups.
Tetraspanin‑7 antibodies in other 
inflammatory disease
With the exception of insulin, all major targets of autoanti-
bodies in type 1 diabetes are expressed outside of the insu-
lin-producing beta cell, typically in cells of neuroendocrine 
origin. Furthermore, all autoantibody targets are intracel-
lular, either by being located in insulin secretory vesicles 
(insulin) or by having autoantibody epitopes localised to 
the cytoplasmic domain of the molecule (GAD65, IA-2, 
ZnT8). Cytoplasmic location of autoantibody epitopes is 
also seen for Tspan7 [44, 45]. Because of this, it is unlikely 
that autoantibodies are directly involved in beta cell destruc-
tion themselves; instead, the selective targeting of beta cells 
by the immune system appears to be related to upregulation 
of MHC class I expression on the cell surface, leading to 
increased recognition by cytotoxic T cells [1]. Autoantibody-
secreting B cells are likely to play a role in this process by 
processing and presenting antigen to both helper and cyto-
toxic T cells, facilitating their activation and function [49].
The expression of autoantigens in multiple organs may 
have significance in the development of other inflammatory 
diseases. For example, autoantibodies to GAD65, which is 
highly expressed in the brain, are described in several other 
autoimmune conditions, including Stiff Person Syndrome 
and polyendocrine autoimmune syndromes [50, 51]. Tspan7 
is expressed in the brain, kidneys, liver and lung, as well as 
in pancreatic islets, and there is evidence that Tspan7 may 
be involved in an inflammatory disease affecting the lung, 
respiratory tract and kidney, granulomatosis with polyangii-
tis (GPA), formerly known as Wegener’s granulomatosis. 
Prior to the identification of tetraspanin-7 as a target of 
autoantibodies in type 1 diabetes, Thurner et al. determined 
the specificity of variable region immunoglobulin light and 
heavy chain genes from B lymphocytes that had been laser-
dissected from germinal centres of Wegener’s granuloma. 
One of the putative targets identified was TM4SF2, the gene 
encoding tetraspanin-7 [52]. It is not yet clear whether cir-
culating antibodies to Tspan7 are detected in patients with 
GPA. However, approximately 7% of patients with GPA 
co-present with diabetes mellitus; likewise, the presence of 
type 1 diabetes is associated with an increased familial risk 
of GPA [53, 54]. With the establishment of robust assays to 
measure antibodies to Tspan7, it may now be worthwhile 
investigating if they are indeed present in GPA patient 
populations.
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Concluding remarks
Tspan7 is established as an autoantigen in type 1 diabetes 
and may be considered a potential target for antigen-specific 
immune intervention to prevent disease in individuals identi-
fied as being at risk. Tspan7 is predicted to have the typical 
four transmembrane domain structure of the tetraspanin fam-
ily, and the alignment of these domains appears important 
for creating epitopes for autoantibodies in disease, formed by 
the three short cytoplasmic loops linking the transmembrane 
domain. Difficulties in producing antigen with appropriate 
structure, together with the hydrophobic nature of the mol-
ecule, has hampered the development of reliable assays for 
antibodies to the antigen. Better understanding of the struc-
ture of autoantibody epitopes will be important for optimis-
ing Tspan7 antibody assays for prediction and autoimmune 
categorisation of type 1 diabetes, and potentially of other 
organ-specific inflammatory diseases such as GPA. Further-
more, because B cell and T cell epitopes frequently overlap 
[55], the cytoplasmic domains are also likely to harbour T 
cell determinants that could be targets of antigen-specific 
immunotherapy designed to inactivate autoreactive T cells 
in disease. The observation that autoimmunity in type 1 
diabetes is directed to a relatively short regions of Tspan7 
should assist in identifying T cell and B cell epitopes and 
will facilitate future studies to establish the importance of 
Tspan7 autoimmunity in the prediction and prevention of 
type 1 diabetes.
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